Bildkälla: Stockfoto

Bioinvent: Positive Preliminary Results from BI-1206 with Pembrolizumab - Redeye

Redeye is optimistic on BI-1206 in solid cancers in combination with pembrolizumab following the first interim readout of the phase I/IIa trial.

Redeye is optimistic on BI-1206 in solid cancers in combination with pembrolizumab following the first interim readout of the phase I/IIa trial.
Börsvärldens nyhetsbrev
ANNONSER